1. Home
  2. SCYX vs SGA Comparison

SCYX vs SGA Comparison

Compare SCYX & SGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$4.26

Market Cap

60.4M

Sector

Health Care

ML Signal

HOLD

Logo Saga Communications Inc. (FL)

SGA

Saga Communications Inc. (FL)

HOLD

Current Price

$8.95

Market Cap

61.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
SGA
Founded
1999
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
60.4M
61.3M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
SCYX
SGA
Price
$4.26
$8.95
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
329.4K
12.4K
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
9.05%
EPS Growth
61.36
N/A
EPS
N/A
N/A
Revenue
$257,000.00
$124,829,000.00
Revenue This Year
N/A
$6.74
Revenue Next Year
$608.78
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.65
52 Week Low
$0.57
$8.83
52 Week High
$5.62
$14.27

Technical Indicators

Market Signals
Indicator
SCYX
SGA
Relative Strength Index (RSI) 72.96 23.98
Support Level $0.67 N/A
Resistance Level $5.62 $12.02
Average True Range (ATR) 0.27 0.28
MACD 0.26 -0.02
Stochastic Oscillator 73.19 5.19

Price Performance

Historical Comparison
SCYX
SGA

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About SGA Saga Communications Inc. (FL)

Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.

Share on Social Networks: